K Number
K170032
Device Name
QMAPP Amplifier; QMAPP Hemodynamic Monitoring System; QMAPP PCM; QMAPP GO; QMAPP EP
Manufacturer
Date Cleared
2017-09-08

(247 days)

Product Code
Regulation Number
870.2300
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
QMAPP® is intended for use by professional healthcare providers for physiological/hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), end tidal CO2 (EtCO2), fractional flow reserve (FFR), non-invasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG. QMAPP® is intended to be used on the patient population of adults. QMAPP® is not intended for neonatal/infant, pediatric and adolescent patients. OMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment. QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology. OMAPP® can be used standalone and in networked environments. The system is intended for patient/procedural data management, such as documentation, logging, rending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices.
Device Description
The QMAPP® system offers a complete physiological/hemodynamic monitoring and reporting system. The system is built from three units: an Amplifier, Live Monitoring CPU and Reporting CPU. The Amplifier Unit has various sensors connected with the patient, e.g. ECG, SpO2 and NiBP. The Amplifier Unit is connected to the Live Monitoring CPU via a dedicated Ethernet connection. The acquired patient information can be visualized on a Live Monitoring CPU, typically located in the technical room. A software application executed on the Live Monitoring CPU can visualize the patient information. Also the Amplifier Unit can be controlled, i.e. most importantly, set acquisition and filtering parameters for the different sensors, by the Live Monitoring CPU. Optionally the Monitoring unit can be connected via a dedicated Ethernet connection to a Reporting CPU, typically located in the technical room. On the Reporting CPU a database is installed which facilitates data storage and retrieval. A software application executed on the Reporting CPU serves as a patient data management system. It can be used for analysis, calculation and reporting in various representations of patient information. The QMAPP® system, can operate standalone or it can be part of a typical hospital network infrastructure. The latter offers the possibility to send or receive information from and to other devices. The software has several communication modules, based on HL7 or DICOM protocols to interface with third party equipment/systems. The QMAPP® system works with 3rd party 510(k) cleared devices: SpO2 module, (Covidien Nellcor, K083325), NiBP module (CAS Medical Systems, MAXNIBP ND+, e.g. CAS Medical Systems, 740 Select, K150620) and EtCO2 sensors, e.q. CLEO Patient Monitor, K142244.
More Information

Not Found

No
The document explicitly states "Mentions AI, DNN, or ML: Not Found" and the description of the device and its functions does not mention any AI or ML capabilities.

No.
The device is described as a physiological/hemodynamic monitoring system intended for data acquisition, display, and analysis, not for providing therapy.

Yes
Explanation: The device is intended for "physiological/hemodynamic monitoring," "clinical data acquisition, medical image/data processing and analytical assessment," and "analysis, calculation and reporting" of patient information, which are all diagnostic functions.

No

The device description explicitly states the system is built from three units: an Amplifier, Live Monitoring CPU, and Reporting CPU. The Amplifier Unit has various sensors connected to the patient, indicating hardware components beyond just software.

Based on the provided text, the QMAPP® device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly states that QMAPP® is for "physiological/hemodynamic monitoring" and involves measuring various physiological parameters directly from the patient (ECG, respiration, pressures, SpO2, EtCO2, etc.). IVD devices are intended for the examination of specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
  • Device Description: The description details sensors connected directly to the patient and the processing of signals acquired from the patient's body. This aligns with physiological monitoring, not in vitro testing of specimens.
  • Lack of Mention of Specimens: There is no mention of collecting or analyzing biological specimens in the intended use or device description.

The device is a physiological monitoring system used in a clinical setting to acquire and analyze real-time patient data.

N/A

Intended Use / Indications for Use

QMAPP® is intended for use by professional healthcare providers for physiological/hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), end tidal CO2 (EtCO2), fractional flow reserve (FFR), non-invasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG.

QMAPP® is intended to be used on the patient population of adults. QMAPP® is not intended for neonatal/infant, pediatric and adolescent patients.

OMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment.

QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology.

OMAPP® can be used standalone and in networked environments. The system is intended for patient/procedural data management, such as documentation, logging, rending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices.

Product codes (comma separated list FDA assigned to the subject device)

MWI, DQK

Device Description

The QMAPP® system offers a complete physiological/ hemodynamic monitoring and reporting system. The system is built from three units: an Amplifier, Live Monitoring CPU and Reporting CPU. The Amplifier Unit has various sensors connected with the patient, e.g. ECG, SpO2 and NiBP. The Amplifier Unit is connected to the Live Monitoring CPU via a dedicated Ethernet connection. The acquired patient information can be visualized on a Live Monitoring CPU, typically located in the technical room. A software application executed on the Live Monitoring CPU can visualize the patient information. Also the Amplifier Unit can be controlled, i.e. most importantly, set acquisition and filtering parameters for the different sensors, by the Live Monitoring CPU. Optionally the Monitoring unit can be connected via a dedicated Ethernet connection to a Reporting CPU, typically located in the technical room. On the Reporting CPU a database is installed which facilitates data storage and retrieval. A software application executed on the Reporting CPU serves as a patient data management system. It can be used for analysis, calculation and reporting in various representations of patient information.

The QMAPP® system, can operate standalone or it can be part of a typical hospital network infrastructure. The latter offers the possibility to send or receive information from and to other devices. The software has several communication modules, based on HL7 or DICOM protocols to interface with third party equipment/systems.

The QMAPP® system works with 3rd party 510(k) cleared devices: SpO2 module, (Covidien Nellcor, K083325), NiBP module (CAS Medical Systems, MAXNIBP ND+, e.g. CAS Medical Systems, 740 Select, K150620) and EtCO2 sensors, e.q. CLEO Patient Monitor, K142244.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Adults. Not intended for neonatal/infant, pediatric and adolescent patients.

Intended User / Care Setting

professional healthcare providers / cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology.

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Non-Clinical Tests: Bench testing was carried out on the following characteristics: Electrocardiograph (ECG), Heart rate, SpO2, NiBP, IBP, Cardiac Output, Intra cardiac ECG, Skin Temperature, ECG impedance for Rate of respiratory effort, Measurement accuracy, Electromagnetic compatibility (EMC), Electrical safety testing, Mechanical safety testing, Software verification and validation testing.

Usability Testing: Usability testing was also conducted. Usability validation was presented in the Clinical Performance Section 20 of the 510(k). No clinical studies for safety and effectiveness were required.

Clinical validation is carried out on the following characteristics: NIBP.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K131497, K130626

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).

(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).

0

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

September 8, 2017

Fysicon B.V. % Patsy Trisler JD, RAC, Consultant Qserve Group US Inc. 5600 Wisconsin Avenue Chevy Chase, Maryland 20815

Re: K170032

Trade/Device Name: QMAPP®, QMAPP® GO, QMAPP® AP and QMAPP® EP Regulation Number: 21 CFR 870.2300 Regulation Name: Cardiac Monitor (Including Cardiotachometer And Rate Alarm) Regulatory Class: Class II Product Code: MWI, DQK Dated: August 8. 2017 Received: August 9, 2017

Dear Patsy Trisler:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device

1

related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely.

M.A. Willemsen

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K170032

Device Name

QMAPP, QMAPP® GO, QMAPP® AP and QMAPP® EP

Indications for Use (Describe)

QMAPP® is intended for use by professional healthcare providers for physiological/hemodynamic monitoring. The system may be used to display and analyze surface ECG (Electrocardiogram), respiration, invasive pressures, pulse oximetry (SpO2), end tidal CO2 (EtCO2), fractional flow reserve (FFR), non-invasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG.

QMAPP® is intended to be used on the patient population of adults. QMAPP® is not intended for neonatal/infant, pediatric and adolescent patients.

OMAPP® provides also clinical data acquisition, medical image/data processing and analytical assessment.

QMAPP® is intended for use in the areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology.

OMAPP® can be used standalone and in networked environments. The system is intended for patient/procedural data management, such as documentation, logging, rending, storing, reviewing, carrying out clinical calculations and exporting various representations of the acquired data. Data may also be acquired from and/or send to other devices, such as physiological monitoring system, information management systems, image acquisition/storage devices and other medical devices.

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

510(k) Summary – K170032

| Submitter Name:
Submitter Address: | Fysicon B.V.
Hoogheuvelstraat 114,
5349 BA Oss
Netherlands |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phone Number: | +31 (0)412 653 333 |
| Fax Number: | +31 (0)412 653 330 |
| Contact Person: | C.W.A. (Eric) van Antwerpen |
| Date Prepared: | 30-Aug-2017 |
| Device Trade
Name: | QMAPP®, QMAPP® GO, QMAPP® AP and QMAPP® EP |
| Common Name: | Vital Signs Monitoring System |
| Classification
Name, Number &
Product Code: | Programmable diagnostic computer, 21 CFR 870.1425 (DQK);
Monitor, Physiological, Patient (Without Arrhythmia Detection Or
Alarms), 21 CFR 870.2300 (MWI) |
| Classification
Panel: | Cardiovascular |
| Primary Predicate
Device: | K131497, McKesson CardiologyTM Hemo, McKesson Israel Ltd. |
| Secondary
Predicate Device: | K130626, Mac-Lab, CardioLab, ComboLab, SpecialsLab
Recording Systems v6.9.5, GE Healthcare (GE Medical
Systems Technologies, Inc.) |
| Device
Description: | The QMAPP® system offers a complete physiological/
hemodynamic monitoring and reporting system. The system is
built from three units: an Amplifier, Live Monitoring CPU and
Reporting CPU. The Amplifier Unit has various sensors
connected with the patient, e.g. ECG, SpO2 and NiBP. The
Amplifier Unit is connected to the Live Monitoring CPU via a
dedicated Ethernet connection. The acquired patient information
can be visualized on a Live Monitoring CPU, typically located in
the technical room. A software application executed on the Live
Monitoring CPU can visualize the patient information. Also the
Amplifier Unit can be controlled, i.e. most importantly, set
acquisition and filtering parameters for the different sensors, by
the Live Monitoring CPU. Optionally the Monitoring unit can be
connected via a dedicated Ethernet connection to a Reporting |

4

CPU, typically located in the technical room. On the Reporting CPU a database is installed which facilitates data storage and retrieval. A software application executed on the Reporting CPU serves as a patient data management system. It can be used for analysis, calculation and reporting in various representations of patient information.

The QMAPP® system, can operate standalone or it can be part of a typical hospital network infrastructure. The latter offers the possibility to send or receive information from and to other devices. The software has several communication modules, based on HL7 or DICOM protocols to interface with third party equipment/systems.

The QMAPP® system works with 3rd party 510(k) cleared devices: SpO2 module, (Covidien Nellcor, K083325), NiBP module (CAS Medical Systems, MAXNIBP ND+, e.g. CAS Medical Systems, 740 Select, K150620) and EtCO2 sensors, e.q. CLEO Patient Monitor, K142244.

Accessories intended for use with QMAPP®:

Part#Description
0156703110 Lead (IEC) ECG Trunk cable, (K120010)
0156700210 Lead (IEC) Lead wire set, (K120010)
0156703210 Lead (AHA) ECG Trunk cable, (K120010)
0156703310 Lead (AHA) Lead wire set, (K120010)
015670565 Lead (IEC) ECG Trunk cable, (K120010)
015672585 Lead (IEC) Lead wire set, (K120010)
01567034Dual Pressure Adapter Cable, (K120010)
01567022IBP Connection cable for BD/Argon (K120010)
01567024IBP Connection cable for Medex/ACIST (K120010)
01567023IBP Connection cable for
Namic/Navilyst/Angiodynamics (K120010)
01567020IBP Connection cable for Utah Medical (K120010)
01567021IBP Connnection cable for Edwards/Baxter,
(K120010)
01567025SpO2 connection cable for Nellcor, (K120010)
01567053Reusable Adult Silicone SpO2 finger sensor,
(K120010)
01567063Dual Temperature Adapter Cable, (K120010)
01567029Reusable Central temperature probe - Adults,
(K120010)
01567027Reusable Skin temperature probe - Adults,
(K120010)
01567026Reusable Interconnection cable for disp. Probes
(K120010)
On requestDisp. central temperature probe - Adults (24 pcs)
(K120010)
On requestDisp. skin temperature probe - Adults (24 pcs)
(K120010)
01567065NiBP Hose 250 cm
01593003UltraCheck® Reusable Cuff (18–26cm), Small adult,
(K122365)

5

| K170032 | | QMAPP®
Premarket Notification: Traditional 510(k) |
|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Submitter:
Fysicon BV | | |
| | 01593004 | UltraCheck® Reusable Cuff (26–35cm), Adult,
(K122365) |
| | 01593005 | UltraCheck® Reusable Cuff (29–38cm), Adult long,
(K122365) |
| | 01593006 | UltraCheck® Reusable Cuff (32–42cm), Large Adult,
(K122365) |
| | 01593007 | UltraCheck® Reusable Cuff (35–44cm), L Adult Long,
(K122365) |
| | 01593008 | UltraCheck® Reusable Cuff (42–50cm), Thigh
(K122365) |
| | 01567060 | CO Y-Cable
(K012226) |
| | 01567029 | Reference probe (Central temperature probe)
(K120010) |
| | | Disposables and accessories (tranducers, cannulas and
intubation devices) are not part of QMAPP®, but are supplied by
the end user facility as required. |
| Physical
Description: | QMAPP® Amplifier dimensions: 298 x 233 x 47 mm, Weight +/-
2200g, Power External 24 VDC | |
| Intended Use/
Indication for Use
Statement: | QMAPP® is intended for use by professional healthcare providers
for physiological/hemodynamic monitoring. The system may be
used to display and analyze surface ECG (Electrocardiogram),
respiration, invasive pressures, pulse oximetry (SpO2), end tidal
CO2 (EtCO2), fractional flow reserve (FFR), non-invasive blood
pressure (NiBP), surface body temperature, cardiac output and
intra-cardiac ECG. | |
| | QMAPP® is intended to be used on the patient population of
adults. QMAPP® is not intended for neonatal/infant, pediatric and
adolescent patients. | |
| | QMAPP® provides also clinical data acquisition, medical
image/data processing and analytical assessment. | |
| | QMAPP® is intended for use in the areas of, but not limited to
cardiology, cardiac catheterization, electrophysiology, radiology,
invasive radiology. | |
| | QMAPP® can be used standalone and in networked
environments. The system is intended for patient/procedural data
management, such as documentation, logging, reporting,
trending, storing, reviewing, carrying out clinical calculations and
exporting various representations of the acquired data. Data may
also be acquired from and/or send to other devices, such as
physiological monitoring system, information management
systems, image acquisition/storage devices and other medical
devices. | |
| Summary of
Technological
Characteristics | The QMAPP® system offers vital signs measuring, visualization,
monitoring and analysis. The QMAPP® Amplifier offers Surface
ECG (Electrocardiogram), respiration, invasive pressures, pulse | |

6

oximetry (SpO2), end tidal CO2 (EtCO2), Respiration effort, noninvasive blood pressure (NiBP), surface body temperature, cardiac output and intra-cardiac ECG measurements. Typically made in areas of, but not limited to cardiology, cardiac catheterization, electrophysiology, radiology, invasive radiology.

The vital signs data is transferred to a Live Monitoring CPU, which offers visualization of the vital sign information. The vital signs information can also be transferred to a Reporting CPU, which offers data storage, connection to Hospital Information Systems and PACS. The Reporting CPU also offers vital signs analysis and reports capabilities

The predicate devices have the same fundamental technological characteristics as the QMAPP® device. However, QMAPP® is considerably newer technology and the primary difference between the proposed and primary predicate is the primary predicate does not have the added feature of intra-cardiac monitoring using EP catheters, however, the secondary predicate includes that feature.

FeatureSubject DevicePrimary PredicateSecondary Predicate
510(k) NumberK170032K131497K130626
Trade nameQMAPP®, QMAPP®
GO, QMAPP® AP and
QMAPP® EPMcKesson
Cardiology™ HemoMac-Lab, CardioLab,
ComboLab,
SpecialsLab Recording
Systems v6.9.5
ManufacturerFysicon BVMcKesson Israel Ltd.GE Healthcare
Regulation &
Product Code21 CFR 870.1425,
DQK
Programmable
diagnostic computer
21 CFR 870.2300,
MWI
Cardiac monitor21 CFR 870.1425,
DQK
Programmable
diagnostic computer
21 CFR 870.2300,
MWI
Cardiac monitor21 CFR 870.1425,
DQK
Programmable
diagnostic computer
Intended Use
(summary)physiological/hemody
namic monitoring,
recording and
reporting systemsamesame
MONITORS
SURFACE ECGYesYesYes
MONITORS
HEART RATEYesYesYes
MONITORS
RESPIRATION
EFFORTYesYesYes
MONITORS
NIBPYesYesYes
MONITORS
OXYGEN
SATURATIONYesYesYes

7

| MONITORS

IBPYesYesYes
MONITORS
SKIN
TEMPERATUREYesYesYes
MONITORS
CARDIAC
OUTPUTYesYesYes
MONITORS
EtCO2YesYesYes
MONITORS
Intra Cardiac
ECGYesNoYes

Non-Clinical Tests: Bench testing was carried out on the following characteristics:

  • Electrocardiograph (EGG) ●
  • Heart rate
  • . SpO2
  • NiBP
  • . IBP
  • Cardiac Output
  • Intra cardiac ECG
  • Skin Temperature
  • ECG impedance for Rate of respiratory effort
  • Measurement accuracy ●
  • Electromagnetic compatibility (EMC)
  • . Electrical safety testing
  • Mechanical safety testing
  • Software verification and validation testing ●

Usability Testing:

In addition to the above, usability testing was also conducted.

Referenced Standards and Performance Testing:

The QMAPP® system was tested and meets the requirements of following performance Standards.

  • . IEC 60601-2-27:2011 Medical Electrical Equipment - Part 2-27: Particular Requirements for The Basic Safety and Essential Performance of Electrocardiographic Monitoring Equipment.
  • . IEC 80601-2-30:2010 Medical Electrical Equipment - Part 2-30: Particular Requirements for The Basic Safety and Essential Performance of Automated Non-Invasive Sphygmomanometers.
  • IEC 60601-2-34:2011 Medical Electrical Equipment - Part 2-34: Particular Requirements for The Basic Safety, Including Essential Performance, Of Invasive Blood Pressure Monitoring Equipment.

8

IEC 60601-2-49:2011 Medical electrical equipment -- Part 2-49: Particular requirements for the basic safety and essential performance of multifunction patient monitoring equipment. ISO 80601-2-56:2009 Medical Electrical Equipment - Part 2-56: Particular Requirements for Basic Safety and Essential Performance of Clinical Thermometers for Body Temperature Measurement. ISO 80601-2-61:2011 Medical electrical equipment -- Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment.
Clinical
Performance Data:Usability validation was presented in the Clinical Performance
Section 20 of the 510(k). No clinical studies for safety and
effectiveness were required.
Clinical validation is carried out on the following characteristics: NIBP
Referenced Standards and Performance Testing:
The QMAPP system was tested and meets the requirements of
following reference standard: IEC 81060-2:2009 Non-invasive sphygmomanometers –
Part 2: Clinical validation of automated measurement type
Conclusion:The following comparison table shows the similarities and
differences in technological characteristics. None of the
differences raise new questions of safety and effectiveness.

The non-clinical data support the safety of the device and the
hardware and software verification and validation testing
demonstrate that the QMAPP® system should perform as
intended in the specified use conditions. |
| Statement of
Substantial
Equivalence: | The intended use of the QMAPP® system is the same as both the
Predicate and Reference devices, and the technological
characteristics are similar. Per this information and the data
provided, this 510(k) submission supports a substantial
equivalence determination for the QMAPP® |